Alberta researchers say discovery could be 'game changer' for diabetic researchScientists identify new molecular pathway that manages the amount of insulin produced by the body. Jardiance: new “flozin” now available for type 2 diabetesThird SGLT2 inhibitor in Canada reduces cardiovascular risk in Canadian-led clinical trial. Saxenda: new option for chronic weight management Higher-dose liraglutide product intended as an adjunct to diet and increased physical activity. Clinical Feature: Confronting diabetes challenges Practical strategies to optimize care and outcomes in diabetes management. Canadian Diabetes Association issues 2015 interim diabetes guidelines update Incorporates data on sodium-glucose linked transporter 2 (SGLT2) inhibitors for type 2 diabetes. Prepregnancy diabetes accounts for increasing proportion of congenital anomalies Canadian study recommends enhanced periconceptional glycemic control to mitigate risk. Insulin pump therapy associated with lower cardiovascular mortality Swedish study shows superior cardiovascular safety compared with multiple daily insulin injections. SGLT2 inhibitors: possible link to an increased risk of ketoacidosis Health Canada begins safety review for “flozin” drug class. Does sitagliptin increase cardiovascular risk in diabetes patients? New study shows no apparent increased risk of major adverse cardiovascular events or hospitalization for heart failure. Metformin bad for fish First Previous 31 32 33 34 35 Next Last
